Editor’s note: this article was published in the Aug. 1, 2024 issue of Pharmaceutical Technology Europe®
Syngene’s protein production platform uses a cell line and transposon-based technology licensed from Switzerland-based ExcellGene.
Syngene International, a contract research, development, and manufacturing organization (CRDMO), now offers a new protein production platform aimed at rapid protein synthesis. The platform uses a cell line and transposon-based technology that Syngene licensed from ExcellGene, a Switzerland-based service provider specializing in mammalian cell line development.
Editor’s note: this article was published in the Aug. 1, 2024 issue of Pharmaceutical Technology Europe®
The new protein synthesis platform, combined with Syngene’s clone selection and development processes, offers significant improvement in efficiency and precision. The platform offers faster preclinical and clinical development and shorter timelines to product launches, shortening time to market. Advantages include up to 10 weeks reduction in time versus traditional cell line development methods; better predictability and protein yields, with high-titer levels of up to 10 g/L achieved; support for a variety of modalities, including monoclonal antibodies, biosimilars, bispecific antibodies, antibody drug conjugates, and other recombinant proteins. In addition, the platform’s versatility facilitates integration with perfusion and fed-batch manufacturing processes.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.